AU2017301901B2 - Expression of pten-long with oncolytic viruses - Google Patents

Expression of pten-long with oncolytic viruses Download PDF

Info

Publication number
AU2017301901B2
AU2017301901B2 AU2017301901A AU2017301901A AU2017301901B2 AU 2017301901 B2 AU2017301901 B2 AU 2017301901B2 AU 2017301901 A AU2017301901 A AU 2017301901A AU 2017301901 A AU2017301901 A AU 2017301901A AU 2017301901 B2 AU2017301901 B2 AU 2017301901B2
Authority
AU
Australia
Prior art keywords
cells
pten
cancer
subject
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017301901A
Other languages
English (en)
Other versions
AU2017301901A1 (en
Inventor
Balveen Kaur
Luke Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of AU2017301901A1 publication Critical patent/AU2017301901A1/en
Application granted granted Critical
Publication of AU2017301901B2 publication Critical patent/AU2017301901B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017301901A 2016-07-29 2017-07-31 Expression of pten-long with oncolytic viruses Active AU2017301901B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368822P 2016-07-29 2016-07-29
US62/368,822 2016-07-29
US201762479671P 2017-03-31 2017-03-31
US62/479,671 2017-03-31
PCT/US2017/044683 WO2018023114A1 (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Publications (2)

Publication Number Publication Date
AU2017301901A1 AU2017301901A1 (en) 2019-02-21
AU2017301901B2 true AU2017301901B2 (en) 2024-08-29

Family

ID=61016870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017301901A Active AU2017301901B2 (en) 2016-07-29 2017-07-31 Expression of pten-long with oncolytic viruses

Country Status (8)

Country Link
US (2) US20200085890A1 (enExample)
EP (2) EP4403229A3 (enExample)
JP (3) JP7638061B2 (enExample)
KR (1) KR102780496B1 (enExample)
CN (1) CN110087662A (enExample)
AU (1) AU2017301901B2 (enExample)
SG (1) SG11201900815UA (enExample)
WO (1) WO2018023114A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
SG11202101581RA (en) * 2017-08-09 2021-03-30 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CN108484780A (zh) * 2018-04-16 2018-09-04 河南大学 一种融合蛋白PTEN-L-p53及其应用
US20220169997A1 (en) * 2019-04-12 2022-06-02 Therapten Biosciences Inc. Compositions and methods to manufacture tumor suppressor fusions
KR20220038485A (ko) * 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
CN111763260B (zh) * 2020-06-11 2022-03-29 四川大学华西医院 一种PTEN-Long多克隆抗体及其制备方法和用途
WO2024163335A2 (en) * 2023-01-30 2024-08-08 The Board Of Regents Of The University Of Texas System Pten gene therapy vectors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US8658778B2 (en) * 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
BRPI1005951A2 (pt) * 2009-02-17 2016-10-11 Univ Columbia polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5
MX2012009565A (es) * 2010-02-17 2014-02-27 Univ Columbia Uso de la secuencia lider de pten largo para la liberacion de moleculas transmembrana.
EP2563919B1 (en) * 2010-04-26 2018-06-13 Green Cross Corporation Tumor-specific promoter and oncolytic virus vector comprising the same
EP2494978A1 (en) * 2011-03-03 2012-09-05 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
US9863935B2 (en) * 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
US20160060652A1 (en) 2013-03-13 2016-03-03 Lapian's Corp Microvesicle and method for producing the same
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer

Also Published As

Publication number Publication date
EP3490574A1 (en) 2019-06-05
EP3490574B1 (en) 2024-05-22
EP4403229A3 (en) 2024-08-14
US20230338443A1 (en) 2023-10-26
JP2024123088A (ja) 2024-09-10
JP2019523008A (ja) 2019-08-22
JP7638061B2 (ja) 2025-03-03
CN110087662A (zh) 2019-08-02
SG11201900815UA (en) 2019-02-27
EP4403229A2 (en) 2024-07-24
WO2018023114A1 (en) 2018-02-01
KR20190035782A (ko) 2019-04-03
JP2022163182A (ja) 2022-10-25
AU2017301901A1 (en) 2019-02-21
EP3490574B8 (en) 2024-07-10
EP3490574A4 (en) 2020-03-04
KR102780496B1 (ko) 2025-03-11
CA3032412A1 (en) 2018-02-01
US20200085890A1 (en) 2020-03-19
BR112019001737A2 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
US20230338443A1 (en) Expression of pten-long with oncolytic viruses
US20120027725A1 (en) Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US20230048681A1 (en) Compositions and methods of treatment for lytic and lysogenic viruses
JP7546295B2 (ja) ヒトアンジェルマン症候群において父方ｕｂｅ３ａ遺伝子発現を復活させるための組成物および方法
US20180208914A1 (en) Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic
EP3788070A1 (en) Compositions and methods for hemoglobin production
CN119907694A (zh) 转基因盒
CA3032412C (en) Expression of pten-long with oncolytic viruses
HK40114297A (en) Expression of pten-long with oncolytic viruses
HK40004120A (en) Expression of pten-long with ocolytic viruses
HK40004120B (en) Expression of pten-long with ocolytic viruses
KR20260022337A (ko) KIF1A 연관 신경학적 장애의 치료를 위한 KIF1A 미스센스 돌연변이를 타겟팅하는 RNAi
BR112019001737B1 (pt) Vírus herpes simplex (hsv) oncolítico recombinante compreendendo um gene pten-long e seu uso para inibição da metástase de um câncer
WO2017070113A1 (en) Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer
US20230174940A1 (en) Overcoming immune suppression with tgf-b resistant nk cells
US20160032290A1 (en) Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer
EP4720295A2 (en) Grna for targeting mutant allele and uses thereof
CN121197406A (zh) 靶向ipo5的抑制剂在制备抗核内复制病毒药物中的应用
WO2013098381A1 (en) Rna interference to activate stem cells

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KAUR, BALVEEN AND RUSSELL, LUKE

FGA Letters patent sealed or granted (standard patent)